OraSure Technologies (OSUR) Getting Somewhat Favorable News Coverage, Analysis Finds
News headlines about OraSure Technologies (NASDAQ:OSUR) have trended somewhat positive this week, Accern reports. The research group identifies positive and negative news coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. OraSure Technologies earned a coverage optimism score of 0.19 on Accern’s scale. Accern also assigned headlines about the medical instruments supplier an impact score of 46.1021886963629 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
These are some of the headlines that may have impacted Accern’s scoring:
- OraSure Technologies (OSUR) Rating Increased to Hold at Zacks Investment Research (americanbankingnews.com)
- OraSure Technologies, Inc. (OSUR) Receives Average Rating of “Buy” from Analysts (americanbankingnews.com)
- Why OraSure Technologies, Inc. Rallied 10.8% in December (finance.yahoo.com)
- Mix Thrust In Focus on: TripAdvisor, Inc. (NASDAQ:TRIP), OraSure Technologies, Inc. (NASDAQ:OSUR) – Investing News Update (investingbizz.com)
- OraSure Technologies to Present at the 36th Annual JP Morgan Healthcare Conference – Nasdaq (nasdaq.com)
OraSure Technologies (NASDAQ:OSUR) opened at $19.39 on Thursday. The stock has a market cap of $1,180.00, a P/E ratio of 37.29, a PEG ratio of 4.58 and a beta of 1.27. OraSure Technologies has a 52 week low of $8.39 and a 52 week high of $23.01.
Several brokerages have recently issued reports on OSUR. Zacks Investment Research upgraded shares of OraSure Technologies from a “hold” rating to a “buy” rating and set a $25.00 target price on the stock in a research note on Wednesday, September 20th. ValuEngine downgraded shares of OraSure Technologies from a “buy” rating to a “hold” rating in a research note on Thursday, November 2nd. Jefferies Group downgraded shares of OraSure Technologies from a “buy” rating to a “hold” rating in a research note on Thursday, November 2nd. BidaskClub upgraded shares of OraSure Technologies from a “hold” rating to a “buy” rating in a research note on Thursday, December 21st. Finally, Canaccord Genuity reiterated a “buy” rating and issued a $22.00 target price on shares of OraSure Technologies in a research note on Tuesday, September 19th. Three analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of $19.65.
In related news, Director Mara G. Aspinall acquired 5,000 shares of the stock in a transaction that occurred on Tuesday, November 7th. The shares were bought at an average price of $14.23 per share, for a total transaction of $71,150.00. Following the completion of the transaction, the director now directly owns 5,000 shares in the company, valued at $71,150. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 6.40% of the stock is owned by corporate insiders.
OraSure Technologies Company Profile
OraSure Technologies, Inc (OraSure) is involved in the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using its technologies, as well as other diagnostic products, including immunoassays and other in vitro diagnostic tests that are used on other specimen types.
Receive News & Ratings for OraSure Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies and related companies with MarketBeat.com's FREE daily email newsletter.